Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EMBO, EMBC and the National Science Council of Taiwan Sign Cooperation Agreement

Published: Thursday, November 29, 2012
Last Updated: Thursday, November 29, 2012
Bookmark and Share
New ways of global scientific interaction have been created following a cooperation agreement between EMBO, the European Molecular Biology Conference (EMBC), and the National Science Council of Taiwan (NSC).

The agreement will allow Taiwanese scientists to participate in EMBO training programmes and activities. It also means that EMBO Courses & Workshops can take place at Taiwanese research institutes.

This is the first cooperation agreement of its kind between EMBO, EMBC and Taiwanese scientists, represented by NSC and Academia Sinica. The Taipei City-based Academia Sinica and NSC work together to create new opportunities for Taiwanese life scientists.


“EMBO promotes and encourages the development of the life sciences within Europe and beyond. We encourage the global mobility of scientists and we look forward to the increased scientific collaboration that this agreement will bring,” said EMBO Director Maria Leptin.

EMBO Associate Member and Academia Sinica President Chi-Huey Wong said: “EMBO is a leading organization that fosters new generations of life science researchers producing world-class scientific results. It is our delight to create great opportunities for young Taiwanese scientists to connect with the elite scientists of Europe.”

Representing the NSC, the cooperation agreement was signed by Minister Cyrus C.Y. Chu. He said: “This agreement opens up a gateway for Taiwanese life scientists to interact with some of the world’s brightest minds. We anticipate that more Taiwanese scientists will form affiliations with leading European life scientists because of this agreement.”

Under the terms of the agreement, scientists can apply for EMBO Short-Term and Long-Term Fellowships. Young Taiwanese group leaders will be eligible to benefit from the EMBO Young Investigator Programme, which provides outstanding young scientists with financial, academic and practical support to start up their first independent research laboratories.

Taiwanese scientists and EMBO will also cooperate in the organization of EMBO Courses & Workshops, which will help to spark collaborations between different scientific disciplines. Earlier this year, Academia Sinica and EMBO jointly organized the lecture course “Logic of Regulatory Circuits in Life Sciences” in Taipei City.

Conference organizers can apply for funding for plenary lectures given by EMBO Members or lectures given by EMBO Young Investigators at Taiwanese institutes and universities. Travel stipends will be available for Taiwanese scientists to attend EMBO Courses & Workshops and The EMBO Meeting.

The cooperation agreement will run for three years.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pancreatic Stem Cells Isolated from Mice
Scientists have succeeded in growing stem cells that have the ability to develop into two different types of cells that make up a healthy pancreas.
Tuesday, September 17, 2013
Cancer Stem Cells Isolated from Kidney Tumours
Scientists have isolated cancer stem cells that lead to the growth of Wilms’ tumours, a type of cancer typically found in the kidneys of young children.
Friday, December 14, 2012
Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!